ResMed (RMD) PT Raised to $250 at Wolfe Research
- Tech, megacaps drag Wall St to lower close as big market week kicks off
- Recession EV price wars have started, expected another 15-20% in cuts - Chowdhry
- Johnson & Johnson shares tumble on reports talc unit bankruptcy case dismissed by appeals court
- 'Don't Fight the Fed' is still alive and this week will serve as a reminder - MS Wilson
- Ford to cut prices while 'significantly' increasing Mach-E production amid Tesla cuts
Wolfe Research analyst Mike Polark raised the price target on ResMed (NYSE: RMD) to $250.00 (from $230.00) while maintaining a Outperform rating.
You May Also Be Interested In
- ResMed (RMD:AU) (RMD) PT Raised to AUD36.50 at JPMorgan
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
- Stifel sees strength ahead of Starbucks’ (SBUX) 1Q comp report
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!